Rani Therapeutics is developing a novel technology platform to convert injectable drugs such as TNFα inhibitors, interleukin antibodies, basal insulin and GLP-1 into oral pills. Rani currently has pharmaceutical collaborations with Novartis and Astra Zeneca.
Rani entered into a collaboration with Novartis to evaluate Rani's novel oral biotherapeutics drug delivery platform in mid-2015.
Rani entered into a collaboration with MedImmune to evaluate Rani's novel oral drug delivery platform in the Metabolic Disease field in early 2016. MedImmune is the global biologics research and development arm of AstraZeneca.
The delivery of large molecules orally is considered the holy grail of drug delivery. We understand the magnitude of the problem we are pursuing, and we are confident that our approach has the potential to radically change the way biologics are administered to patients.